This upregulates the Meox1-Cxcr6/Ccl5 axis, enhances CD8+ T cell infiltration in tumours, and sensitises MSS-CRC to combined radiotherapy and immunotherapy (Fig. 6i). Here, CXCR6 is linked to neoplasm.